Plasma Galectin-3 and urine proteomics predict FEV(1) improvement in omalizumab-treated patients with severe allergic asthma: Results from the PROXIMA sub-study()

BACKGROUND: Patients with severe allergic asthma (SAA) when treated with omalizumab may exhibit different extent of response. Identifying biomarkers that can predict the extent of treatment effectiveness in patients can be useful in personalizing omalizumab treatment. METHODS: Patients from the long...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:World Allergy Organ J
Autors principals: Riccio, Anna Maria, Mauri, Pierluigi, De Ferrari, Laura, Rossi, Rossana, Di Silvestre, Dario, Bartezaghi, Marta, Saccheri, Fabiana, Canonica, Giorgio Walter
Format: Artigo
Idioma:Inglês
Publicat: World Allergy Organization 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6992845/
https://ncbi.nlm.nih.gov/pubmed/32015785
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.waojou.2019.100095
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars